The stock of BioXcel Therapeutics Inc (NASDAQ:BTAI) last traded at $0.35, up 1.36% from the previous session.
BTAI stock price is now -33.63% away from the 50-day moving average and -72.35% away from the 200-day moving average. The market capitalization of the company currently stands at $17.36M.
With the price target reduced from $9 to $4, UBS Downgraded its rating from Buy to Neutral for BioXcel Therapeutics Inc (NASDAQ: BTAI). On August 15, 2023, Mizuho Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $40 to quote $4, while ‘Guggenheim’ rates the stock as ‘Neutral’
In other news, O’Neill Vincent, insider sold 165 shares of the company’s stock on Dec 16 ’24. The stock was sold for $58 at an average price of $0.35. Upon completion of the transaction, the insider now directly owns 19,957 shares in the company, valued at $6984.95. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 16 ’24, CEO and President Mehta Vimal sold 3,117 shares of the business’s stock. A total of $1,131 was realized by selling the stock at an average price of $0.36. This leaves the insider owning 59,605 shares of the company worth $20861.75. A total of 17.18% of the company’s stock is owned by insiders.
During the past 12 months, BioXcel Therapeutics Inc has had a low of $0.30 and a high of $4.17. The fifty day moving average price for BTAI is $0.53274 and a two-hundred day moving average price translates $1.28242 for the stock.
The latest earnings results from BioXcel Therapeutics Inc (NASDAQ: BTAI) was released for 2024-06-30. The net profit margin was -3119.33% and return on equity was -1766.94% for BTAI. The company reported revenue of $0.21 million for the quarter, compared to $0.34 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -37.24 percent.
